tumor derived urinary exosomal long non coding rnas as diagnostic biomarkers for bladder cancer
0301 basic medicine
0303 health sciences
Bladder cancer
610
Urine
LncRNA
urine
3. Good health
Exosome
03 medical and health sciences
lncRNA
exosome
bladder cancer
Original Article
info:eu-repo/classification/ddc/610
DOI:
10.17877/de290r-21723
Publication Date:
2020-01-01
AUTHORS (6)
ABSTRACT
Bladder cancer (BC) is the sixth most common malignancy in men and 17th in women. Exosomal long non-coding RNAs (lncRNAs) have been defined as a novel biomarker for BC. The aim of this study is to evaluate the clinical significance of urine exosomal PVT-1, ANRIL and PCAT-1 as a biomarker in BC patients with tumors classified as T1 or T2. Exosomes were isolated from urine of BC patients and healthy donors, then characterized according to their shape, size, and exosome markers by Electron Microscopy, Dynamic light scattering, and Western blotting. Exosomal lncRNAs extraction was done to determine the expression levels of PVT-1, ANRIL and PCAT-1 by qRT-PCR. ANRIL and PCAT-1 expression was significantly higher in BC patients compared to normal subjects. To evaluate the performance of the identified lncRNAs for BC detection, we performed ROC curves analysis. The diagnostic accuracy of ANRIL and PCAT-1, measured by AUC, was 0.7229 (sensitivity = 46.67 % and specificity = 87.5 %) and 0.7292 (sensitivity = 43.33 % and specificity = 87.5 %). Transcript levels of lncRNAs in urinary exosomes are potential diagnostic biomarkers in bladder cancer.<br/>EXCLI Journal; 19:Doc301; ISSN 1611-2156<br/>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES ()
CITATIONS ()
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....